Quarterly & Annual Financial Results
Alembic Pharmaceuticals Reports Resilient Q4 FY26 Performance with 29% YoY Growth in Net Profit
NSE
APLLTD
BSE
533573
Alembic Pharmaceuticals Limited announced its audited financial results for Q4 FY26 and FY26, reporting steady revenue growth and strong profitability improvement. The company achieved 4% YoY growth in revenue from operations and 29% YoY growth in net profit during Q4 FY26, supported by operational discipline, US business growth, and expansion into the US branded pharmaceuticals market.
PRICE-SENSITIVE TRIGGER
Event: Announcement of audited Q4 FY26 and FY26 financial results.
Type: Quarterly & Annual Financial Results
Impact: Positive
Immediate Effect: Improved profitability, healthy EBITDA margins, and strategic entry into the US branded pharmaceutical business may strengthen investor confidence and support long-term growth expectations.
Key Metrics:
- Q4 FY26 Revenue from Operations: Rs. 1,848 Cr
- Q4 FY26 Revenue Growth YoY: 4%
- Q4 FY26 Profit After Tax: Rs. 203 Cr
- Q4 FY26 PAT Growth YoY: 29%
- Q4 FY26 EBITDA (Pre R&D): Rs. 455 Cr
- Q4 FY26 EBITDA Growth YoY: 8%
- Q4 FY26 EBITDA Margin: 25%
- India Business Revenue Q4 FY26: Rs. 568 Cr
- US Formulation Revenue Q4 FY26: Rs. 564 Cr
- Ex-US Revenue Q4 FY26: Rs. 369 Cr
- API Business Revenue Q4 FY26: Rs. 347 Cr
- FY26 Total Revenue: Rs. 7,345 Cr
- FY26 Revenue Growth YoY: 10%
Highlight Metric:
- Q4 FY26 Net Profit Growth: 29% YoY
What Happened ?
Alembic Pharmaceuticals Limited released its audited financial results for the quarter and financial year ended March 31, 2026, highlighting resilient operational and financial performance.
The company reported Q4 FY26 revenue from operations of Rs. 1,848 crore, up 4% year-on-year, while Profit After Tax increased 29% YoY to Rs. 203 crore. EBITDA before R&D expenses rose 8% YoY to Rs. 455 crore, with EBITDA margin standing at 25%.
Operationally, Alembic reported growth across key segments including India branded business and US formulations business. The company also announced its entry into the US branded pharmaceuticals market through Alembic Therapeutics with the commercial launch of Pivya®.
During the quarter, Alembic achieved six launches in the US market and received four ANDA approvals. The India branded business continued to perform steadily across gynecology, gastroenterology, ophthalmology, and animal healthcare segments.
Key Details
- Revenue from operations increased 4% YoY to Rs. 1,848 Cr in Q4 FY26.
- Profit After Tax rose 29% YoY to Rs. 203 Cr.
- EBITDA pre-R&D grew 8% YoY to Rs. 455 Cr.
- EBITDA margin stood at 25%.
- India branded business revenue reached Rs. 568 Cr.
- US formulations business grew 11% YoY to Rs. 564 Cr.
- Six product launches completed in the US market during the quarter.
- Four ANDA approvals received during Q4 FY26.
- API business revenue increased 2% YoY to Rs. 347 Cr.
- Company launched its US branded pharmaceuticals business through Alembic Therapeutics.
- Commercial launch of Pivya® marked entry into focused branded specialty portfolio in the US.
- FY26 total revenue reached Rs. 7,345 Cr, reflecting 10% YoY growth.
Additional Note:
- Management highlighted that disciplined execution, operational delivery, and strategic investments supported profitability improvement and long-term growth positioning during FY26.
Risk Analysis
Key Risks:
- Dependence on US pharmaceutical market performance and pricing environment.
- Regulatory risks related to US FDA inspections and product approvals.
- Competition in generic pharmaceuticals affecting margins.
- Currency fluctuation risks due to international operations.
- Execution risks associated with expansion into branded pharmaceuticals in the US.
- R&D spending requirements and pipeline commercialization uncertainty.
Worst Case Scenario:
- Regulatory setbacks, pricing pressure in the US generics market, delayed product approvals, or weak demand in key markets could impact revenue growth and profitability.
Risk Level: Medium
Company Commentary
- Management stated that Q4 FY26 reflected disciplined execution across businesses.
- Alembic highlighted continued focus on profitability and operational delivery.
- The company emphasized its strategic entry into the US branded pharmaceuticals market.
- Management noted strong performance across key business segments.
- Alembic reiterated commitment toward long-term growth investments and value creation.
Official Exchange Filing: Alembic Pharmaceuticals Limited